Breakthroughs on the Horizon: The Future of Duchenne Muscular Dystrophy Treatments

The landscape of Duchenne muscular dystrophy (DMD) therapy is poised for significant advancement in 2025. While several treatments have entered the market recently, there remains considerable unmet need for the approximately 15,000 Americans living with DMD. With multiple companies developing the next generation of treatments, and established regulatory pathways in place, experts anticipate that new options will soon be available.

2025: A Year of Promising Breakthroughs

Michael Kelly, Chief Scientific Officer at CureDuchenne, an organization that invests in several DMD-focused companies, believes 2025 will be a defining year. “I expect 2026 to be equally promising as companies align their clinical studies with potential readouts and approvals,” Kelly said. CureDuchenne supports Sarepta Therapeutics, Avidity Biosciences, Dyne Therapeutics, and Capricor Therapeutics, among others.

The journey to DMD therapy began in 1986 with the discovery of the dystrophin gene. However, it took 30 years for the first DMD treatment to secure FDA approval. Since then, eight therapies have been approved within eight years, marking substantial progress against this life-limiting neuromuscular disease. Recent years, particularly, have witnessed a surge in innovation, including the FDA’s 2023 approval of Sarepta Therapeutics’ Elevidys, the first gene therapy for DMD.

Continuing the Push for Efficacy

Despite these advancements, there is still a need for increased efficacy. “There’s still more efficacy that we’re hoping for,” observed Christiana Bardon, managing partner of MPM BioImpact.

Several companies are tackling this challenge. Dyne Therapeutics, Avidity Biosciences, and Wave Life Sciences are among the organizations working on improved treatments. Their efforts include new gene therapies and enhanced exon skippers that promise greater efficacy.

Exon Skippers: The Evolution of DMD Therapies

Four of the eight approved therapies for DMD are exon-skipping drugs, which use antisense oligonucleotides to bypass non-functional exons, enabling the body to produce a functional dystrophin protein segment. These therapies are effective for specific mutation sets in the DMD population.

Sarepta Therapeutics dominates the exon-skipping market with Exondys 51, Vyondys 53, and Amondys 45. Together, these approved treatments address approximately 30% of the DMD patient population. Despite their safety, these first-generation exon skippers are limited in their efficacy, producing only 1-2% of the dystrophin protein level seen in non-DMD individuals.

Michael Kelly pointed out the need for better drug delivery mechanisms. Next-generation exon skippers incorporate targeting moieties and utilize endosomal escape pathways to enhance delivery and increase dystrophin expression.

Wave Life Sciences is developing an exon 53 skipper called WVE-N531, which showed consistent 9% dystrophin expression in a Phase II trial in September 2024. Dyne Therapeutics also announced similar results with their candidate DYNE-251.

Avidity Biosciences is targeting the under-served exon 44 population with del-zota, which demonstrated a striking 25% increase in dystrophin production and near-normal creatine kinase levels in Phase I/II trials.

Gene Therapies: The Road to Transformative Treatment

Sarepta’s Elevidys, approved in June 2024, is the first gene therapy for DMD. It is currently indicated for both ambulatory and non-ambulatory patients aged 4 years and older with confirmed DMD mutations, potentially covering up to 80% of the DMD population.

Elevidys uses an adeno-associated virus (AAV) delivery system but faces challenges due to patient antibodies that render some ineligible for treatment. Sarepta is investigating methods to treat these antibody-positive patients to extend Elevidys’ reach.

Michael Kelly suggested that the DMD gene’s complexity limits the efficacy of current gene therapies. Elevidys utilizes a truncated version of the dystrophin gene, which sacrifices some protein functionality for manageability within the AAV vector.

Regenxbio’s gene therapy candidate RGX-202 addresses this issue with a smaller promoter, allowing for a slightly larger dystrophin gene version. Early Phase I/II trial results were encouraging, with improvements in strength and time function tests. A pivotal Phase III trial has commenced, with a BioLicense Application (BLA) planned for 2026.

Expanding Therapeutic Reach Beyond Skeletal Muscle

Resolving DMD’s manifestations in cardiac and respiratory tissues is crucial for patient well-being. Next-generation therapies aim to address these areas.

Marbán discussed deramiocel, a treatment derived from donor heart cells. It exhibits anti-inflammatory, immunomodulatory, antifibrotic, and pro-regenerative properties. Clinical trials have shown deramiocel significantly slows disease progression, including cardiac function decline—a critical aspect of DMD management.

“DMD has become the test case for orphan disease research, driving therapeutic development,” Marbán concluded. “We now have tools that were previously unavailable, and more are on the horizon for 2025.”

Conclusion: A Strong Push for Better DMD Treatments

The progress made in DMD therapy over the past few years is commendable, but there is an unmet need for more effective treatments. Companies like Wave Life Sciences, Dyne Therapeutics, and Avidity Biosciences are making strides with advanced exon skippers, while gene therapy innovators such as Sarepta Therapeutics and Regenxbio are pushing the boundaries of genetic modification.

As we look toward 2025, the combination of these efforts promises significant advancements in treating DMD. With improved delivery mechanisms, more comprehensive gene therapy options, and a broader therapeutic impact, the future of DMD treatment looks hopeful.

We encourage readers to stay informed about these developments and provide feedback on how these advancements could impact the lives of individuals with DMD. Share your thoughts and experiences below or subscribe to our newsletter for more updates on this and other groundbreaking medical research.